• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SOX9-B7x 轴保护去分化的肿瘤细胞免受免疫监视,从而推动乳腺癌的进展。

A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.

机构信息

Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

出版信息

Dev Cell. 2023 Dec 4;58(23):2700-2717.e12. doi: 10.1016/j.devcel.2023.10.010. Epub 2023 Nov 13.

DOI:10.1016/j.devcel.2023.10.010
PMID:37963469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10842074/
Abstract

How dedifferentiated stem-like tumor cells evade immunosurveillance remains poorly understood. We show that the lineage-plasticity regulator SOX9, which is upregulated in dedifferentiated tumor cells, limits the number of infiltrating T lymphocytes in premalignant lesions of mouse basal-like breast cancer. SOX9-mediated immunosuppression is required for the progression of in situ tumors to invasive carcinoma. SOX9 induces the expression of immune checkpoint B7x/B7-H4 through STAT3 activation and direct transcriptional regulation. B7x is upregulated in dedifferentiated tumor cells and protects them from immunosurveillance. B7x also protects mammary gland regeneration in immunocompetent mice. In advanced tumors, B7x targeting inhibits tumor growth and overcomes resistance to anti-PD-L1 immunotherapy. In human breast cancer, SOX9 and B7x expression are correlated and associated with reduced CD8 T cell infiltration. This study, using mouse models, cell lines, and patient samples, identifies a dedifferentiation-associated immunosuppression mechanism and demonstrates the therapeutic potential of targeting the SOX9-B7x pathway in basal-like breast cancer.

摘要

去分化的干细胞样肿瘤细胞如何逃避免疫监视仍知之甚少。我们发现,在去分化的肿瘤细胞中上调的谱系可塑性调节因子 SOX9 限制了鼠基底样乳腺癌癌前病变中浸润性 T 淋巴细胞的数量。SOX9 介导的免疫抑制是原位肿瘤进展为浸润性癌所必需的。SOX9 通过 STAT3 激活和直接转录调控诱导免疫检查点 B7x/B7-H4 的表达。B7x 在去分化的肿瘤细胞中上调,并保护它们免受免疫监视。B7x 还可保护免疫活性小鼠的乳腺再生。在晚期肿瘤中,B7x 靶向抑制肿瘤生长并克服对抗 PD-L1 免疫治疗的耐药性。在人乳腺癌中,SOX9 和 B7x 的表达呈正相关,并与 CD8 T 细胞浸润减少相关。本研究使用小鼠模型、细胞系和患者样本,确定了一种与去分化相关的免疫抑制机制,并证明了靶向 SOX9-B7x 通路在基底样乳腺癌中的治疗潜力。

相似文献

1
A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.SOX9-B7x 轴保护去分化的肿瘤细胞免受免疫监视,从而推动乳腺癌的进展。
Dev Cell. 2023 Dec 4;58(23):2700-2717.e12. doi: 10.1016/j.devcel.2023.10.010. Epub 2023 Nov 13.
2
Host b7x promotes pulmonary metastasis of breast cancer.宿主 b7x 促进乳腺癌肺转移。
J Immunol. 2013 Apr 1;190(7):3806-14. doi: 10.4049/jimmunol.1202439. Epub 2013 Mar 1.
3
Structure and cancer immunotherapy of the B7 family member B7x.B7家族成员B7x的结构与癌症免疫治疗
Cell Rep. 2014 Nov 6;9(3):1089-98. doi: 10.1016/j.celrep.2014.09.053. Epub 2014 Oct 30.
4
Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8 T Cells.肿瘤浸润髓系细胞表达的共抑制分子 B7 超家族成员 1 诱导抗肿瘤 CD8 T 细胞功能障碍。
Immunity. 2018 Apr 17;48(4):773-786.e5. doi: 10.1016/j.immuni.2018.03.018. Epub 2018 Apr 3.
5
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.上皮细胞表达的 B7-H4 驱动了小鼠和人乳腺癌的免疫治疗反应差异。
Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468.
6
B7x in cancer immunity and immunotherapy.B7x 在癌症免疫和免疫治疗中的作用。
Int Immunopharmacol. 2023 May;118:110133. doi: 10.1016/j.intimp.2023.110133. Epub 2023 Apr 5.
7
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.B7 免疫检查点作为神经内分泌肿瘤治疗的靶点。
Endocr Relat Cancer. 2021 Feb;28(2):135-149. doi: 10.1530/ERC-20-0337.
8
Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.宿主B7-H4缺陷与吉西他滨治疗对小鼠模型肿瘤消退和抗肿瘤T细胞免疫的协同作用。
Cancer Immunol Immunother. 2017 Apr;66(4):491-502. doi: 10.1007/s00262-016-1950-2. Epub 2017 Jan 10.
9
B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.B7-H4 在携带有 EGFR 激活突变的肺腺癌中增加,并有助于免疫抑制。
Oncogene. 2022 Jan;41(5):704-717. doi: 10.1038/s41388-021-02124-6. Epub 2021 Nov 27.
10
Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.B7-H3 和 B7-H4 表达在乳腺导管原位癌中的临床病理特征与 T 细胞浸润的相关性。
Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):767-775. doi: 10.1097/PAI.0000000000000817.

引用本文的文献

1
Applications and techniques of single-cell RNA sequencing across diverse species.跨多种物种的单细胞RNA测序的应用与技术
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf354.
2
Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities.癌症干细胞与免疫疗法的关联:关键见解、挑战及潜在治疗机遇
Cancers (Basel). 2025 Jun 23;17(13):2100. doi: 10.3390/cancers17132100.
3
Spatial Transcriptome Analysis of B7-H4 in Head and Neck Squamous Cell Carcinoma: A Novel Therapeutic Target for Anti-Immune Checkpoint Inhibitors.

本文引用的文献

1
MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state.MLL3 缺失通过促进混合上皮-间充质转化状态驱动转移。
Nat Cell Biol. 2023 Jan;25(1):145-158. doi: 10.1038/s41556-022-01045-0. Epub 2023 Jan 5.
2
A single-cell and spatially resolved atlas of human breast cancers.人类乳腺癌的单细胞和空间分辨图谱。
Nat Genet. 2021 Sep;53(9):1334-1347. doi: 10.1038/s41588-021-00911-1. Epub 2021 Sep 6.
3
Establishment and long-term culture of mouse mammary stem cell organoids and breast tumor organoids.
头颈部鳞状细胞癌中B7-H4的空间转录组分析:抗免疫检查点抑制剂的新型治疗靶点
Head Neck Pathol. 2025 Jun 30;19(1):78. doi: 10.1007/s12105-025-01815-w.
4
Cancer stem cells and niches: challenges in immunotherapy resistance.癌症干细胞与微环境:免疫治疗耐药性面临的挑战
Mol Cancer. 2025 Feb 25;24(1):52. doi: 10.1186/s12943-025-02265-2.
5
Role of the SOX family in cancer immune evasion: Emerging player and promising therapeutic opportunities.SOX家族在癌症免疫逃逸中的作用:新兴角色与潜在治疗机遇
Medicine (Baltimore). 2025 Jan 31;104(5):e41393. doi: 10.1097/MD.0000000000041393.
6
Stemness in solid malignancies: coping with immune attack.实体恶性肿瘤中的干性:应对免疫攻击。
Nat Rev Cancer. 2025 Jan;25(1):27-40. doi: 10.1038/s41568-024-00760-0. Epub 2024 Oct 25.
7
Identifying subtypes and developing prognostic models based on N6-methyladenosine and immune microenvironment related genes in breast cancer.基于N6-甲基腺嘌呤和免疫微环境相关基因识别乳腺癌亚型并建立预后模型。
Sci Rep. 2024 Jul 18;14(1):16586. doi: 10.1038/s41598-024-67477-w.
8
The potential role of CD8+ cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer.CD8+ 细胞毒性 T 淋巴细胞和组织驻留记忆细胞的一个分支在非腔乳腺癌中的潜在作用。
PeerJ. 2024 Jul 10;12:e17667. doi: 10.7717/peerj.17667. eCollection 2024.
9
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.上皮细胞表达的 B7-H4 驱动了小鼠和人乳腺癌的免疫治疗反应差异。
Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468.
建立和长期培养小鼠乳腺干细胞类器官和乳腺肿瘤类器官。
STAR Protoc. 2021 May 29;2(2):100577. doi: 10.1016/j.xpro.2021.100577. eCollection 2021 Jun 18.
4
Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.癌细胞在恶性进展过程中回溯一个逐步分化的程序。
Cancer Discov. 2021 Oct;11(10):2638-2657. doi: 10.1158/2159-8290.CD-20-1637. Epub 2021 Apr 28.
5
SOX factors as cell-state regulators in the mammary gland and breast cancer.SOX因子作为乳腺和乳腺癌中的细胞状态调节因子。
Semin Cell Dev Biol. 2021 Jun;114:126-133. doi: 10.1016/j.semcdb.2021.01.002. Epub 2021 Feb 12.
6
Genomic Alterations during the to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.免疫系统塑造的从导管原位癌到浸润性导管乳腺癌的基因组改变。
Mol Cancer Res. 2021 Apr;19(4):623-635. doi: 10.1158/1541-7786.MCR-20-0949. Epub 2020 Dec 18.
7
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌(KEYNOTE-355):一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
8
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.抑制 B7-H4 糖基化可恢复免疫冷型乳腺癌的抗肿瘤免疫。
Cancer Discov. 2020 Dec;10(12):1872-1893. doi: 10.1158/2159-8290.CD-20-0402. Epub 2020 Sep 16.
9
Heterotypic cell-cell communication regulates glandular stem cell multipotency.异型细胞间通讯调节腺体干细胞多能性。
Nature. 2020 Aug;584(7822):608-613. doi: 10.1038/s41586-020-2632-y. Epub 2020 Aug 26.
10
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.IL6/STAT3 信号通路劫持雌激素受体 α 增强子以驱动乳腺癌转移。
Cancer Cell. 2020 Sep 14;38(3):412-423.e9. doi: 10.1016/j.ccell.2020.06.007. Epub 2020 Jul 16.